Hyperbaric Oxygen Therapy for Diabetic Foot Ulcers

Hyperbaric Oxygen Therapy for Diabetic Foot Ulcers

Hafez Selim

44,35 €
IVA incluido
Disponible
Editorial:
Dr. Hafez Selim MD, PhD
Año de edición:
2026
ISBN:
9798237887198
44,35 €
IVA incluido
Disponible
Añadir a favoritos

A practical, evidence-based clinical guide to deciding when hyperbaric oxygen therapy belongs in diabetic foot ulcer care - and when it does not.Hyperbaric oxygen therapy (HBOT) remains one of the most debated adjuncts in advanced wound care. Positive trials and biological rationale coexist with negative modern studies, low-certainty recommendations, treatment burden, and uncommon but serious risks.For clinicians facing a nonhealing foot ulcer, the question is not whether HBOT always works or never works. It is whether this patient is likely to benefit after perfusion, infection control, debridement, offloading, metabolic management, and adequate standard care have been addressed.This clinician-focused guide will help readers:Understand why diabetic foot ulcers fail to heal and where wound hypoxia may contribute.Evaluate randomized trials, systematic reviews, guidelines, and conflicting clinical evidence.Distinguish systemic chamber-delivered HBOT from topical and normobaric oxygen therapies.Identify candidates using Wagner grade, perfusion, treatment response, contraindications, and ability to complete therapy.Plan treatment, measure response, and decide when HBOT should be continued or stopped.Recognize adverse effects, serious risks, and essential hyperbaric medicine safety systems.Practical resources include patient-selection and pretreatment safety criteria, the elements of informed consent, monitoring and adverse-event documentation standards, evidence tables, a patient handout, six teaching cases, and a one-page clinical decision algorithm.Written for wound-care physicians, podiatrists, hyperbaric clinicians, vascular specialists, nurses, researchers, and healthcare trainees, this evidence-based clinical guide connects diabetic wound healing, chronic wound management, and limb preservation with disciplined decision-making.HBOT helps some patients, cannot help most, burdens all, and harms a few. This book provides the framework needed to distinguish those groups - and to use HBOT responsibly without overselling its benefits or ignoring its limitations.

Artículos relacionados

Otros libros del autor

  • When Medicines Harm
    Hafez Selim
    When Medicines Harm: Fifty-One Case Histories That Shaped PharmacovigilanceMost drug-safety rules were written after something went wrong. This book tells the story behind each one.In 1937 an untested solvent in a new antibiotic syrup killed more than 100 people, and the United States began requiring proof of safety before a drug could be sold. In the early 1960s a sedative sol...
  • Signal Management in Medical Device Vigilance
    Hafez Selim
    The first book on signal management written for medical devices.Device companies receive complaints, code them, decide what is reportable, and file on time. What most of them lack is an owner for the question that connects all of that work: what does this pattern mean, and what must change because of it? Pharmacovigilance answered that question years ago with a named discipline...
    Disponible

    63,71 €

  • Signal Management in Pharmacovigilance
    Hafez Selim
    A practical, end-to-end guide to pharmacovigilance signal management - from the first disproportionality statistic to the final regulatory decision.Every marketed medicine generates a steady stream of safety data. The hard part is not collecting it but deciding, consistently and defensibly, which patterns are real, which matter, and what to do about them. This book follows the ...
    Disponible

    87,13 €

  • Practical Benefit-Risk Assessment in Pharmacovigilance
    Hafez Selim
    Every periodic safety report ends with one sentence: the benefit-risk balance of the product remains favourable. This book is about how to earn it.Practical Benefit-Risk Assessment in Pharmacovigilance answers the question that guidance documents leave open: you have the efficacy and safety data, so how do you actually decide? Across 33 chapters in seven parts, it follows the r...
    Disponible

    69,32 €